On Thursday, Masimo earned an upgrade to its Relative Strength (RS) Rating, from 90 to 94.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an 80 or better RS Rating at the beginning of a new climb.
How To Use Stock Charts To Stay Profitable And Protected
While Masimo is not near an ideal entry right now, see if it goes on to form and break out from a proper base.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 44%, compared to 31% in the prior report. Revenue increased from 5% to 9%.
Masimo earns the No. 3 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
